|
CN112204401A
|
|
Method for predicting cancer drug responsiveness
|
|
EP3274467A1
|
|
Surrogate functional biomarker for solid tumor cancer
|
|
AU2016206882A1
|
|
Context dependent diagnostics test for guiding cancer treatment
|
|
AU2014342269A1
|
|
Methods for determining chemosensitivity and chemotoxicity
|
|
WO2015017788A1
|
|
Method for predicting cancer sensitivity
|
|
WO2015010094A1
|
|
Differential bh3 mitochondrial profiling
|
|
EP2922544A1
|
|
Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
|
|
US2015133450A1
|
|
Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
|
|
CN111856013A
|
|
Surrogate functional diagnostic test for cancer
|
|
WO2012122370A2
|
|
Compositions and methods useful for treating diseases
|
|
WO2012088438A1
|
|
Compositions and methods useful for treating diseases
|
|
EP3284828A1
|
|
Antibodies specific to heterodimers of bcl-2 family and uses thereof
|
